These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 10440630)

  • 1. Clinical and economic impact of newer versus older antipsychotic medications in a community mental health center.
    Galvin PM; Knezek LD; Rush AJ; Toprac MG; Johnson B
    Clin Ther; 1999 Jun; 21(6):1105-16. PubMed ID: 10440630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of antipsychotic medication on psychiatric service utilization and cost.
    Rothbard A; Murrin MR; Jordan N; Kuno E; McFarland BH; Stroup TS; Morrissey JP; Stiles PG; Boothroyd RA; Merwin E; Shern DL
    J Ment Health Policy Econ; 2005 Jun; 8(2):83-93. PubMed ID: 15998980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, or quetiapine.
    Gianfrancesco F; Pesa J; Wang RH
    J Manag Care Pharm; 2005 Apr; 11(3):220-30. PubMed ID: 15804206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the Impact of Adherence to and Persistence with Atypical Antipsychotic Therapy on Health Care Costs and Risk of Hospitalization.
    Jiang Y; Ni W
    Pharmacotherapy; 2015 Sep; 35(9):813-22. PubMed ID: 26406773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.
    Sikirica V; Pliszka SR; Betts KA; Hodgkins P; Samuelson T; Xie J; Erder H; Dammerman R; Robertson B; Wu EQ
    J Manag Care Pharm; 2012; 18(9):676-89. PubMed ID: 23206211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Looking beyond the formulary budget in cost-benefit analysis.
    Cohen LJ
    Am J Manag Care; 1997 Feb; 3 Suppl():S11-7. PubMed ID: 10180337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
    Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
    J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of newer antipsychotics on outcomes in schizophrenia.
    Keks NA
    Clin Ther; 1997; 19(1):148-58; discussion 126-7. PubMed ID: 9083717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals.
    Essock SM; Frisman LK; Covell NH; Hargreaves WA
    Arch Gen Psychiatry; 2000 Oct; 57(10):987-94. PubMed ID: 11015817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The new atypical antipsychotics: a review of pharmacoeconomic studies.
    Revicki DA
    Expert Opin Pharmacother; 2000 Jan; 1(2):249-60. PubMed ID: 11249546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
    Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
    Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in taiwan.
    Gau SS; Chung CH; Gau CS
    J Clin Psychopharmacol; 2008 Jun; 28(3):271-8. PubMed ID: 18480683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical antipsychotics and formulary decisions.
    Am J Manag Care; 1998 Jan; 4 Suppl():S8-12; discussion S12-4. PubMed ID: 10184948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economics of atypical antipsychotics in bipolar disorder: a review of the literature.
    Fleurence RL; Dixon JM; Revicki DA
    CNS Drugs; 2006; 20(7):591-9. PubMed ID: 16800717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda.
    Lubinga SJ; Mutamba BB; Nganizi A; Babigumira JB
    Appl Health Econ Health Policy; 2015 Oct; 13(5):493-506. PubMed ID: 25958192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Economic analyses of olanzapine in the treatment of schizophrenia and bipolar disorder].
    Dilla T; Prieto L; Ciudad A; Sacristán JA
    Actas Esp Psiquiatr; 2004; 32(5):269-79. PubMed ID: 15529211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.
    Yang YK; Tarn YH; Wang TY; Liu CY; Laio YC; Chou YH; Lee SM; Chen CC
    Psychiatry Clin Neurosci; 2005 Aug; 59(4):385-94. PubMed ID: 16048443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risperidone. A pharmacoeconomic review of its use in schizophrenia.
    Foster RH; Goa KL
    Pharmacoeconomics; 1998 Jul; 14(1):97-133. PubMed ID: 10182198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.